Last reviewed 2026-04-23 · How we verify

BHV-7000

BHV-7000 is a calcitonin gene-related peptide receptor antagonist.

BHV-7000 is a calcitonin gene-related peptide receptor antagonist. Used for Migraine prevention.

At a glance

Mechanism of action

BHV-7000 works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals. This mechanism is thought to be beneficial in the treatment of migraine and other headache disorders.

Approved indications

• Migraine prevention

Common side effects

• Injection site reactions
• Musculoskeletal pain
• Nausea

Key clinical trials

• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures (PHASE2, PHASE3)
• Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (PHASE2, PHASE3)
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (PHASE2, PHASE3)
• BHV-7000 Responsive Neurostimulation System (RNS) Study (PHASE1)
• Long-term Safety and Tolerability of BHV-7000 (PHASE2)
• A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia (PHASE1)
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression (PHASE2)
• BHV-7000 Acute Treatment of Bipolar Mania (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BHV-7000 CI brief — competitive landscape report
• BHV-7000 updates RSS · CI watch RSS
• Biohaven Therapeutics Ltd. portfolio CI